Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mitoxantrone
Drug ID BADD_D01480
Description An anthracenedione-derived antineoplastic agent.
Indications and Usage For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
Marketing Status Prescription; Discontinued
ATC Code L01DB07
DrugBank ID DB01204
KEGG ID D08224
MeSH ID D008942
PubChem ID 4212
TTD Drug ID D0R3JB
NDC Product Code 61703-343; 0703-4685; 0703-4686; 0703-4680
Synonyms Mitoxantrone | Mitozantrone | DHAQ | NSC-279836 | NSC 279836 | NSC279836 | NSC-287836 | NSC 287836 | NSC287836 | NSC-299195 | NSC 299195 | NSC299195 | NSC-301739 | NSC 301739 | NSC301739 | NSC-301739D | NSC 301739D | NSC301739D | Mitroxone | Pralifan | CL-232325 | CL 232325 | CL232325 | Mitoxantrone Acetate | Acetate, Mitoxantrone | Mitoxantrone Hydrochloride | Hydrochloride, Mitoxantrone | Novantrone | Ralenova | Novantron | Onkotrone
Chemical Information
Molecular Formula C22H28N4O6
CAS Registry Number 65271-80-9
SMILES C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
ApoptosisG1/S-specific cyclin-D1P24385T123558219202; 1450413; 9816016; 7683227; 8096557; 8243566; 8260751; 7915211; 9581849
ApoptosisTranscription factor JunP05412T690858219202; 1450413; 9816016; 7683227; 8096557; 8243566; 8260751; 7915211; 9581849
Cytogenetic investigationsDNA topoisomerase 1P11387T098261997159; 1649059; 1333822; 1540962; 1596908; 1330289; 8382551; 2168279; 2168281; 1319346; 11062742; 1374671; 1646393; 7882360; 1322239; 7688316; 1659821; 8383887; 8144400; 1698546
Toxicity to various agentsEpoxide hydrolase 1P07099Not AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperuricaemia14.09.01.003--
Hypocalcaemia14.04.01.004--
Hypokalaemia14.05.03.002--
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Infection11.01.08.0020.000139%Not Available
Infertility21.03.02.001--Not Available
Injection site extravasation12.07.03.002; 08.02.03.002--Not Available
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Leukopenia01.02.02.0010.000347%Not Available
Liver disorder09.01.08.001--Not Available
Local reaction08.01.03.012--Not Available
Lung disorder22.02.07.001--Not Available
Lymphocyte count abnormal13.01.06.022--Not Available
Lymphocyte count decreased13.01.06.006--
Malaise08.01.01.003--
Menorrhagia21.01.03.002--
Menstrual disorder21.01.01.004--Not Available
Mucosal inflammation08.01.06.002--Not Available
Myalgia15.05.02.001--
Myelodysplastic syndrome16.01.04.001; 01.10.04.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial ischaemia24.04.04.010; 02.02.02.008--Not Available
Nail disorder23.02.05.002--
Nausea07.01.07.001--
Necrosis24.04.02.006; 08.03.03.001--Not Available
Neoplasm16.16.02.0010.000139%Not Available
Nephropathy toxic20.05.03.002; 12.03.01.010--Not Available
Nervous system disorder17.02.10.001--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages